Pharmacy Times offers relevant, clinical information for pharmacists that they can use in their daily practice. These include OTC and Rx product news, disease conditions, patient education guides, drug diversion and abuse, and more.
Issue link: http://pharmacytimes.epubxp.com/i/614520
December 2015 PharmacyTimes.org 107 References 1. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2015;16(1):45-56. doi: 10.1038/nrg3849. 2. Cystic Fibrosis Foundation, Annual data report to the Center Directors 2014. Cystic Fibrosis Foundation. Bethesda, MD 2015:8. 3. Grosse SD, Boyle CA, Botkin JR, et al; CDC. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004;53(RR-13):1-36. 4. Anderson DH. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child. 1938;56:344-399. 5. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125(1 suppl 1):1S-39S. 6. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. New Engl J Med. 2005;352(19):1992-2001. 7. Boyle MP. Strategies for identifying modifier genes in cystic fibrosis. Proc Am Thorac Soc. 2007;4(1):52-57. 8. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol. 1997;24(2):137-142; discussion 159-161. 9. Boucher RC. New concepts of the pathogenesis of cys- tic fibrosis lung disease. Eur Respir J. 2004;23(1):146- 158. 10. Prescott WA Jr, Johnson CE. Antiinflammatory thera- pies for cystic fibrosis: past, present, and future. Pharmacotherapy. 2005;25(4):555-573. 11. Elborn JS. How can we prevent multisystem complica- tions of cystic fibrosis? Semin Respir Crit Care Med. 2007;28(3):303-311. 12. Clancy JP, Jain M. Personalized medicine in cys- tic fibrosis: dawning of a new era. Am J Respir Crit Care Med. 2012;186(7):593-597. doi: 10.1164/ rccm.201204-0785PP. 13. Derichs N. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulatory modulators in cystic fibrosis. Eur Respir Rev. 2013;22(127):58-65. doi: 10.1183/09059180.00008412. 14. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines: chronic medica- tions for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-689. 15. Goss CH, Burns JL. Exacerbations in cystic fibro- sis. 1: Epidemiology and pathogenesis. Thorax. 2007;62(4):360-367. 16. Gaylor AS, Reilly JC. Therapy with macrolides in patients with cystic fibrosis. Pharmacotherapy. 2002;22(2):227-239. 17. Sheehan J, Massie J, Hay M, et al. The natural his- tory and predictors of persistent problem behaviors in cystic fibrosis: a multicenter prospective study. Arch Dis Child. 2012;97(7):625-631. doi: 10.1136/archdi- schild-2011-301527. 18. White D, Stiller K, Haensel N. Adherence of adult cys- tic fibrosis patients with airway clearance and exercise regimens. J Cyst Fibros. 2007;6(3):163-170. 19. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibro- sis. The Pulmozyme Study Group. N Eng J Med. 1994;331(10):637-642. 20. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest. 1996;110(4):889-895. 21. Quan JM, Tiddens HA, Sy JP, et al; Pulmozyme Early Intervention Trial Study Group. A two-year random- ized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr. 2001;139(6):813-820. 22. Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recom- binant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet. 2001;358(9290):1316-1321. 23. Elkins MR, Robinson M, Rose BR, et al; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hyper- tonic saline in patients with cystic fibrosis. N Engl J Med. 2006; 354(3):229-239. 24. Davies JC. New therapeutic approaches for cystic fibrosis lung disease. J R Soc Med. 2002;95(suppl 41):58-67. 25. Konstan MW, Schluchter MDW, Xue W, Davis PB. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Resp Crit Care Med. 2007;176(11):1084-1089. 26. Konstan MW, Byard PJ, Hoppel CL, Davis PBet al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995;332(13):848-854. 27. Saiman L, Anstead M, Mayer-Hamblett N, et al; AZ0004 Azithromycin Study Group. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a random- ized controlled trial. JAMA. 2010;303(17):1707-1715. doi: 10.1001/jama.2010.563. 28. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibro- sis. Am J Respir Crit Care Med. 2003;168(8):918-951. 29. Flume PA, Mogayzel PJ Jr, Robinson KA, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808. doi: 10.1164/ rccm.200812-1845PP. 30. Phan H, Kuhn R. Cystic fibrosis. In: Benavides S, Nahata MC, eds. Pediatric Pharmacotherapy. Lenexa, KS: American College of Clinical Pharmacy; 2013:223. 31. Fusco NM, Toussaint KA, Prescott WA Jr. Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis. Ann Pharmacother. 2015;49(4):458-68. doi: 10.1177/1060028014567526. 32. Dasenbrook EC. Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis. Curr Opin Pulm Med. 2011;17(6):437-441. doi: 10.1097/ MCP.0b013e32834b95ed. 33. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resis- tant Staphylococcus aureus and the rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(8):814-821. doi: 10.1164/rccm.200802- 327OC. 34. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999; 340(1):23-29. 35. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreo- nam lysine for chronic airway Pseudomonas aerugi- nosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921-928. doi: 10.1164/rccm.200712- 1804OC. 36. Cayston [package insert]. Foster City, CA: Gilead Sciences, Inc; 2014. 37. Fiel SB. Aerosolized antibiotics in cystic fibrosis: an update. Expert Rev Respir Med. 2014; 8(3): 305-314. doi: 10.1586/17476348.2014.896205. 38. Sokol RJ, Durie PR; Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. Recommendations for management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1988;:28(suppl 1):S1-S13. 39. Moran A, Pillay K, Becker DJ, Acerini CL; International Society for Pediatric and Adolescent Diabetes. Management of cystic fibrosis-related dia- betes in children and adolescents. Pediatr Diabetes. 2014;15(:suppl 20):65-76. 40. Lubamba B, Dhooghe B, Noel S, Leal T. Cystic fibrosis: insight into CFTR pathophysiology and phar- macotherapy. Clin Biochem. 2012;45(15):1132-1144. doi: 10.1016/j.clinbiochem.2012.05.034. 41. Pettit RS. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Ann Pharmacother. 2012;46(7- 8):1065-1075. doi: 10.1345/aph.1R076. 42. Amin R, Ratjen F. Emerging drugs for cystic fibrosis. Expert Opin Emerg Drugs. 2014;19(1):143-155. doi: 10.1517/14728214.2014.882316. 43. Ramsey BW, Davies J, McElvaney NG, et al; VX08- 770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672. doi: 10.1056/ NEJMoa1105185. 44. De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014;13(6):674-680. doi: 10.1016/j.jcf.2014.09.005. 45. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D- CFTR mutation. N Engl J Med. 2010;363(21):1991- 2003. doi: 10.1056/NEJMoa0909825. 46. Davies JC, Wainwright CE, Canny GJ, et al; VX08- 770-103 (ENVISION) Study Group. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219-1225. doi: 10.1164/rccm.201301-0153OC. 47. Kalydeco [package insert]. Boston, MA: Vertex Pharmaceuticals, Inc; 2015. 48. Flume PA, Liou TG, Borowitz DS, et al; Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. CHEST. 2012;142:718- 724. 49. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR muta- tion. Thorax. 2012;67(1):12-18. doi: 10.1136/tho- raxjnl-2011-200393. 50. Boyle MP, Bell SC, Konstan MW, et al; VX09-809- 102 Study Group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a Phe508del CFTR mutation: a phase II randomized controlled trial. Lancet Respir Med. 2014;2(7):527-538. doi: 10.1016/ S2213-2600(14)70132-8. 51. Wainwright CE, Elborn JS, Ramsey BW, et al; TRAFFIC Study Group; TRANSPORT Study Group. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220-231. doi: 10.1056/NEJMoa1409547. 52. Orkambi [package insert]. Boston, MA: Vertex Pharmaceuticals, Inc; 2015. 53. Vertex. A phase 3 study of VX-661 in combination with ivacaftor in subjects aged 12 years and older with cystic fibrosis, who have one F508del-CFTR mutation and a second mutation that has been demon- strated to be clinically responsive to ivacaftor. Clinical Trials website. https://clinicaltrials.gov/ct2/show/ NCT02412111?term=VX-661&rank;=9. Accessed October 18, 2015. 54. Wilschanski M, Miller LL, Shoseyovvox D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J. 2011;38(1):59- 69. doi: 10.1183/09031936.00120910. 55. Kerem E, Konstan M, De Boeck K, et al; Cystic Fibrosis Ataluren Study Group. A randomized placebo-controlled trial of ataluren for the treatment of nonsense mutation cystic fibrosis. Lancet Respir Med. 2014;2(7):539-547. doi: 10.1016/S2213-2600(14)70100-6. Educational Disclaimer: Continuing professional education (CPE) activities sponsored by Pharmacy Times Continuing Education are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may refect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.